Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Childr...

Por M. Fevzi Ozkaynak, Andrew L. Gilman, Wendy B. London, Arlene Naranjo, Mitchell B. Diccianni, Sheena C. Tenney, Malcolm Smith, Karen S. Messer, Robert Seeger, C. Patrick Reynolds, L. Mary Smith, Barry L. Shulkin, Marguerite Parisi, John M. Maris, Julie R. Park, Paul M. Sondel, Alice L. Yu, Alice L. Yu
Publicado em 2018-07-01